{"insert":{"user_id":"1000300291","type":"misc","id":"43838492"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=403535","label":"url"}],"paper_title":{"en":"血清アルブミンに存在する超硫黄の解析と創薬応用","ja":"血清アルブミンに存在する超硫黄の解析と創薬応用"},"authors":{"en":[{"name":"Ikeda Mayumi"},{"name":"Fukuta Tatsuya"},{"name":"岩尾 康範"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"池田 真由美"},{"name":"福田 達也"},{"name":"岩尾 康範"},{"name":"小田切 優樹"},{"name":"丸山 徹"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"publication_date":"2024-01","publication_name":{"en":"Journal of the Pharmaceutical Society of Japan","ja":"薬学雑誌"},"volume":"144","number":"1","starting_page":"51","ending_page":"56","languages":["jpn"],"identifiers":{"doi":["10.1248/yakushi.23-00162-3"],"issn":["1347-5231"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000300291","type":"misc","id":"30512981"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366421","label":"url"}],"paper_title":{"en":"タンパクのPEG修飾によるPEG免疫応答の誘導","ja":"タンパクのPEG修飾によるPEG免疫応答の誘導"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2020-02-01","publication_name":{"en":"Journal of the Pharmaceutical Society of Japan","ja":"薬学雑誌"},"volume":"140","number":"2","starting_page":"163","ending_page":"169","languages":["jpn"],"identifiers":{"doi":["10.1248/yakushi.19-00187-5"],"issn":["1347-5231"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000300291","type":"misc","id":"30512982"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=362968","label":"url"}],"paper_title":{"en":"臨床応用可能な体腔内投与型RNAi 製剤(DFP-10825)の開発と難治性がんに対する治療","ja":"臨床応用可能な体腔内投与型RNAi 製剤(DFP-10825)の開発と難治性がんに対する治療"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"石田 竜弘"}]},"publication_date":"2020-02-01","publication_name":{"en":"Medchem News","ja":"Medchem News"},"volume":"30","number":"1","starting_page":"19","ending_page":"24","languages":["jpn"],"identifiers":{"doi":["10.14894/medchem.30.1_19"],"issn":["2432-8626"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000300291","type":"misc","id":"30512983"},"force":{"see_also":[{"@id":"https://cir.nii.ac.jp/crid/1390283659849385728/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=362751","label":"url"}],"paper_title":{"en":"リポソームDDS 製剤開発における免疫系の制御と動態解析の重要性","ja":"リポソームDDS 製剤開発における免疫系の制御と動態解析の重要性"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"publication_date":"2020-02","publication_name":{"en":"Oleoscience","ja":"オレオサイエンス"},"volume":"20","number":"2","starting_page":"71","ending_page":"76","languages":["jpn"],"identifiers":{"doi":["10.5650/oleoscience.20.71"],"issn":["2187-3461"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000300291","type":"misc","id":"30512998"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/23933235","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=265735","label":"url"}],"paper_title":{"en":"The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage","ja":"The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage"},"authors":{"en":[{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Ishida Tatsuhiro"},{"name":"Kiwada Hiroshi"}],"ja":[{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"石田 竜弘"},{"name":"際田 弘志"}]},"description":{"en":"Despite the clinical introduction of an increasing number of polyethylene glycol (PEG)-conjugated substances, PEG has been named as the cause of an unexpected immunogenic response known as the \"accelerated blood clearance (ABC) phenomenon.\" This phenomenon has been extensively observed during the repeated administration of PEG-conjugated substances and PEGylated nanocarriers including PEGylated liposomes, PEGylated nanoparticles, PEGylated micelles, etc., resulting in the increased clearance and reduced efficacy of PEG-conjugated substances/PEGylated nanocarriers. In this review, therefore, we focused on the possible mechanisms underlying the induction of such a phenomenon and emphasized the factors affecting its magnitude. In addition, the clinical implications of the ABC phenomenon on the therapeutic efficacy of PEG-conjugated substances/PEGylated nanocarriers, along with the new approaches that can be applied to manage and/or abrogate the induction of the ABC phenomenon, are also discussed.","ja":"Despite the clinical introduction of an increasing number of polyethylene glycol (PEG)-conjugated substances, PEG has been named as the cause of an unexpected immunogenic response known as the \"accelerated blood clearance (ABC) phenomenon.\" This phenomenon has been extensively observed during the repeated administration of PEG-conjugated substances and PEGylated nanocarriers including PEGylated liposomes, PEGylated nanoparticles, PEGylated micelles, etc., resulting in the increased clearance and reduced efficacy of PEG-conjugated substances/PEGylated nanocarriers. In this review, therefore, we focused on the possible mechanisms underlying the induction of such a phenomenon and emphasized the factors affecting its magnitude. In addition, the clinical implications of the ABC phenomenon on the therapeutic efficacy of PEG-conjugated substances/PEGylated nanocarriers, along with the new approaches that can be applied to manage and/or abrogate the induction of the ABC phenomenon, are also discussed."},"publication_date":"2013-08-07","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"172","number":"1","starting_page":"38","ending_page":"47","languages":["eng"],"identifiers":{"doi":["10.1016/j.jconrel.2013.07.026"],"issn":["1873-4995"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000300291","type":"misc","id":"30513022"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=132271","label":"url"}],"paper_title":{"en":"機能性リポソームの開発とその癌治療への応用","ja":"機能性リポソームの開発とその癌治療への応用"},"authors":{"en":[{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"石田 竜弘"}]},"publication_date":"2003-05","publication_name":{"en":"月刊 薬事","ja":"月刊 薬事"},"volume":"45","number":"7","starting_page":"1125","ending_page":"1132","languages":["jpn"],"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000300291","type":"misc","id":"30513023"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=180304","label":"url"}],"paper_title":{"en":"癌とDDS","ja":"癌とDDS"},"authors":{"en":[{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"石田 竜弘"}]},"publication_date":"2003-03","publication_name":{"en":"癌と人","ja":"癌と人"},"volume":"30","starting_page":"28","ending_page":"29","languages":["jpn"],"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000300291","type":"misc","id":"30513027"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/11766990","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=130857","label":"url"}],"paper_title":{"en":"Interactions of Liposomes with Cells In Vitro and In Vivo:Opsonins and Receptors","ja":"Interactions of Liposomes with Cells In Vitro and In Vivo:Opsonins and Receptors"},"authors":{"en":[{"name":"Ishida Tatsuhiro"},{"name":"Harashima H"},{"name":"Kiwada Hiroshi"}],"ja":[{"name":"石田 竜弘"},{"name":"Harashima H"},{"name":"際田 弘志"}]},"description":{"en":"A number of studies have appeared recently on the underlying mechanisms of liposome-cell interactions under in vitro conditions, in which isolated cell populations or cell lines were used. However, our knowledge of how liposomes interact with cells and the parameters that influence this in vivo is limited. We will summarize and discuss the relevant studies on this matter in this article. In addition, researchers in this field have long been aware of the interaction of liposomes with blood (or serum/plasma) proteins in vivo and their potential role in the process of the clearance of liposomes from the circulation. Some of the 'opsonizing' proteins, such as complement components, immunoglobulins, which enhance the interactions of liposomes with 'phagocytic cells' have been identified. However, the issue of which types of opsonins determine the fate of liposomes in vivo and how liposomal physicochemical properties such as size, charge and fluidity play an important role in the process of liposome clearance is not clear. Our own observations of one of opsonins, complement component are reviewed herein. As opposed to the fate of conventional liposomes, we briefly touch on the interaction of surface-modified liposomes, which are designed to avoid interactions with blood proteins and/or cells (sterically stabilized liposomes, long-circulating liposomes) and to actively target specific cells or tissues (targeted liposomes: immunoliposomes). Blood proteins such as opsonins are not usually thought to play an important role in the clearance of such liposomes.","ja":"A number of studies have appeared recently on the underlying mechanisms of liposome-cell interactions under in vitro conditions, in which isolated cell populations or cell lines were used. However, our knowledge of how liposomes interact with cells and the parameters that influence this in vivo is limited. We will summarize and discuss the relevant studies on this matter in this article. In addition, researchers in this field have long been aware of the interaction of liposomes with blood (or serum/plasma) proteins in vivo and their potential role in the process of the clearance of liposomes from the circulation. Some of the 'opsonizing' proteins, such as complement components, immunoglobulins, which enhance the interactions of liposomes with 'phagocytic cells' have been identified. However, the issue of which types of opsonins determine the fate of liposomes in vivo and how liposomal physicochemical properties such as size, charge and fluidity play an important role in the process of liposome clearance is not clear. Our own observations of one of opsonins, complement component are reviewed herein. As opposed to the fate of conventional liposomes, we briefly touch on the interaction of surface-modified liposomes, which are designed to avoid interactions with blood proteins and/or cells (sterically stabilized liposomes, long-circulating liposomes) and to actively target specific cells or tissues (targeted liposomes: immunoliposomes). Blood proteins such as opsonins are not usually thought to play an important role in the clearance of such liposomes."},"publication_date":"2001-12","publication_name":{"en":"Current Drug Metabolism","ja":"Current Drug Metabolism"},"volume":"2","number":"4","starting_page":"397","ending_page":"409","languages":["eng"],"identifiers":{"doi":["10.2174/1389200013338306"],"issn":["1389-2002"]},"misc_type":"introduction_scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000300291","type":"misc","id":"51438168"},"force":{"see_also":[{"@id":"https://www.scopus.com/pages/publications/105020432762","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=459747","label":"url"}],"paper_title":{"en":"Round Table Discussion: The current status and future of DDS materials","ja":"座談会:DDS材料における現状と今後"},"authors":{"en":[{"name":"Ueno Yoshiyuki"},{"name":"Tuji Riichiro"},{"name":"Nishimoto Yutaka"},{"name":"Motosiromizu Takahiro"},{"name":"Ishida Tatsuhiro"},{"name":"Ueda Motoki"},{"name":"Shimizu Taro"},{"name":"Matsumura Yasuhiro"},{"name":"Morimoto Nobuyuki"},{"name":"Yokoyama Masayuki"},{"name":"Shiraishi Koichi"},{"name":"Ohta Kotoe"}],"ja":[{"name":"上野 良之"},{"name":"辻 理一郎"},{"name":"西本 豊"},{"name":"本白水 崇光"},{"name":"石田 竜弘"},{"name":"上田 一樹"},{"name":"清水 太郎"},{"name":"松村 保広"},{"name":"森本 展行"},{"name":"横山 昌幸"},{"name":"白石 貢一"},{"name":"太田 琴恵"}]},"publication_date":"2025-07-01","publication_name":{"en":"Drug Delivery System","ja":"Drug Delivery System"},"volume":"40","number":"3","starting_page":"172","ending_page":"178","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.2745/dds.40.172"],"issn":["0913-5006"]}},"priority":"input_data"}